A detailed history of Invesco Ltd. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 839,455 shares of CPRX stock, worth $20.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
839,455
Previous 994,058 15.55%
Holding current value
$20.1 Million
Previous $15.8 Million 17.94%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$14.68 - $16.92 $2.27 Million - $2.62 Million
-154,603 Reduced 15.55%
839,455 $13 Million
Q1 2024

May 14, 2024

BUY
$13.18 - $17.11 $980,736 - $1.27 Million
74,411 Added 8.09%
994,058 $15.8 Million
Q4 2023

Feb 12, 2024

SELL
$11.78 - $17.29 $1.27 Million - $1.87 Million
-107,954 Reduced 10.51%
919,647 $15.5 Million
Q3 2023

Nov 13, 2023

SELL
$11.69 - $15.02 $2.3 Million - $2.96 Million
-197,013 Reduced 16.09%
1,027,601 $12 Million
Q2 2023

Aug 11, 2023

BUY
$11.5 - $18.08 $1.03 Million - $1.62 Million
89,766 Added 7.91%
1,224,614 $16.5 Million
Q1 2023

May 12, 2023

SELL
$14.34 - $21.05 $4.35 Million - $6.39 Million
-303,353 Reduced 21.09%
1,134,848 $18.8 Million
Q4 2022

Feb 13, 2023

SELL
$12.25 - $19.5 $523,173 - $832,806
-42,708 Reduced 2.88%
1,438,201 $26.8 Million
Q3 2022

Nov 14, 2022

BUY
$7.06 - $15.52 $3.73 Million - $8.19 Million
527,647 Added 55.35%
1,480,909 $19 Million
Q2 2022

Aug 15, 2022

BUY
$6.23 - $8.57 $2.99 Million - $4.11 Million
479,765 Added 101.32%
953,262 $6.68 Million
Q1 2022

May 16, 2022

BUY
$5.31 - $8.31 $2.32 Million - $3.63 Million
437,247 Added 1206.2%
473,497 $3.93 Million
Q4 2021

Feb 14, 2022

SELL
$5.21 - $7.45 $16,833 - $24,070
-3,231 Reduced 8.18%
36,250 $245,000
Q3 2021

Nov 15, 2021

BUY
$4.85 - $6.04 $24,827 - $30,918
5,119 Added 14.9%
39,481 $209,000
Q2 2021

Aug 17, 2021

BUY
$4.29 - $6.05 $13,972 - $19,704
3,257 Added 10.47%
34,362 $198,000
Q1 2021

May 17, 2021

SELL
$3.45 - $4.69 $15,576 - $21,175
-4,515 Reduced 12.68%
31,105 $143,000
Q4 2020

Feb 16, 2021

BUY
$2.97 - $3.83 $21,692 - $27,974
7,304 Added 25.79%
35,620 $119,000
Q3 2020

Nov 16, 2020

SELL
$2.97 - $5.08 $40,374 - $69,057
-13,594 Reduced 32.44%
28,316 $84,000
Q2 2020

Aug 14, 2020

BUY
$3.48 - $5.05 $44,982 - $65,276
12,926 Added 44.6%
41,910 $194,000
Q1 2020

May 15, 2020

BUY
$2.61 - $5.21 $21,691 - $43,300
8,311 Added 40.2%
28,984 $111,000
Q4 2019

Feb 14, 2020

SELL
$3.67 - $5.7 $1.37 Million - $2.13 Million
-373,673 Reduced 94.76%
20,673 $77,000
Q3 2019

Nov 14, 2019

BUY
$3.89 - $7.43 $1.53 Million - $2.93 Million
394,346 New
394,346 $2.09 Million
Q1 2019

May 15, 2019

SELL
$2.11 - $5.33 $54,125 - $136,725
-25,652 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$1.92 - $3.62 $49,251 - $92,860
25,652 New
25,652 $49,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.46B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.